Keyword: elenbecestat

Biogen headquarters

2. Elenbecestat

Biogen and Eisai’s BACE inhibitor elenbecestat was the last drug in the class still standing when it finally hit the buffers in September, closing another chapter in the troubled story of amyloid-targeting drugs to treat Alzheimer’s disease.
Fail sign

2019’s top 15 clinical trial flops (and a flip-flop)

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.